Saredutant
From Self-sufficiency
| File:Saredutant.png | |
| Systematic (IUPAC) name | |
|---|---|
|
N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)- 2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide | |
| Identifiers | |
| CAS Number | 142001-63-6 |
| ATC code | none |
| PubChem | CID 104974 |
| Chemical data | |
| Formula | C31H35Cl2N3O2 |
| Molar mass | 552.5345 g/mol |
Saredutant (SR-48,968) is a drug which acts as a NK2 receptor antagonist. It was under development by Sanofi-Aventis as a novel antidepressant and anxiolytic and made it to phase III clinical trials. However, in May of 2009, Sanofi-Aventis published its quarterly results and announced the cessation of 14 research/development projects, among which was saredutant for the treatment of major depressive disorder.[1].
See also
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 35px | This drug article relating to the nervous system is a stub. You can help ssf by expanding it. |
- ↑ http://www.sanofi-aventis.com/binaries/Lettre18_FR_Web_acc_tcm29-25341.pdf Letter to the stockholders of Sanofi-Aventis on May 2009
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Chemical articles using a fixed chemical formula
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Antidepressants
- Anxiolytics
- NK2 receptor antagonists
- Acetanilides
- Piperidines
- Organochlorides
- Benzamides
- Nervous system drug stubs
